DNLI - Denali begins dosing in phase 1/2 trial of DNL593 to treat frontotemporal dementia

Denali Therapeutics (NASDAQ:DNLI) said dosing began in a phase 1/2 trial of DNL593 to treat a type of dementia called frontotemporal dementia (FTD) caused by mutations in the granulin gene (GRN). Denali has partnered with Takeda Pharmaceutical (NYSE:TAK) to co-develop and co-commercialize DNL593. The phase 1/2 trial is a three-part study and dosing has begun in Part A, which is a single ascending dose study in healthy volunteers. FTD, which causes behavior and language problems, is characterized by deficiency of progranulin — a type of protein found on the GRN gene — in the brain and is most common form of dementia in people under 60 years of age. The therapy, DNL593, is expected to work by slowing or preventing progression of FTD-GRN by increasing intracellular and extracellular levels of progranulin.

For further details see:

Denali begins dosing in phase 1/2 trial of DNL593 to treat frontotemporal dementia